Esophageal Cancer

Esophageal Cancer: treatments, trials & survival

Esophageal cancer treatment has improved with immunotherapy combinations. Explore current treatment options, clinical trials, and support resources.

New Cases (2024)
22,370
5-Yr Survival
21.7%
Annual Deaths
16,130
Trend
Adenocarcinoma increasing
See active trials

About Esophageal Cancer

Esophageal cancer treatment has improved with immunotherapy combinations. Explore current treatment options, clinical trials, and support resources.

According to the National Cancer Institute’s SEER database, an estimated 22,370 new cases of esophageal cancer will be diagnosed in the United States in 2024, with approximately 16,130 deaths. The overall 5-year relative survival rate is 21.7%.

Source: NCI SEER Data: 1975–2022

Treatment options

Current treatment approaches for esophageal cancer depend on the stage at diagnosis, tumor characteristics, and the patient’s overall health. The most common options include:

1
Surgery (Esophagectomy)
2
Chemotherapy
3
Radiation Therapy
4
Chemoradiation
5
Immunotherapy (Nivolumab + Chemotherapy)
6
Targeted Therapy (Trastuzumab for HER2+)

Treatment recommendations should always be discussed with a qualified oncologist. The options listed above are based on current clinical guidelines and may vary case by case.

Stages

Staging describes the extent of cancer in the body and is crucial for planning the most appropriate treatment:

Stage 0 Stage I Stage II Stage III Stage IV

Known risk factors

Understanding risk factors can support prevention and early detection. Known risk factors for this cancer include:

GERD/Barrett's esophagus
Smoking
Heavy alcohol use
Obesity
Hot beverages
Diet low in fruits/vegetables

Not sure where to start?

A patient navigator familiar with esophageal cancer can help you understand your options and connect you with top US hospitals. Free & confidential.

Active clinical trials

Clinical trials offer access to cutting-edge treatments not yet widely available. The trials below are sourced in real time from ClinicalTrials.gov:

Frequently asked questions

The 5-year relative survival rate for esophageal cancer is 21.7%. When found at an early localized stage, the rate improves to 47%.
Treatment typically involves chemoradiation followed by surgery for resectable disease. Advanced cases are treated with immunotherapy (nivolumab) combined with chemotherapy.
Barrett's esophagus is a condition where chronic acid reflux changes the esophageal lining. It increases the risk of esophageal adenocarcinoma and requires regular endoscopic surveillance.
Yes, the combination of nivolumab with chemotherapy has become first-line treatment for advanced esophageal cancer, showing improved survival compared to chemotherapy alone.
You’re not alone

Looking for esophageal cancer treatment options?

A patient navigator can help you explore treatment pathways, find clinical trials near you, and connect with specialists who see esophageal cancer every day. Free, confidential consultation.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.